What Does Horizon Space Acquisition II ($HSPT) Do? - SPAC Merger Outlook, Market Cap, and Related Stocks Comprehensive Guide
Horizon Space Acquisition II (HSPT) is a SPAC nearing a merger with Taiwanese biotech firm SL Bio, and is expected to trade on Nasdaq under the ticker 'SLBT' after the deal closes.
Subscribe🏢 What kind of company is this?
Horizon Space Acquisition II (HSPT) is a Special Purpose Acquisition Company (SPAC), a 'shell' entity that must find a merger target within a set deadline. The sponsor is Horizon Space Acquisition II Sponsor Corp, with CEO and Chairman Mingyu (Michael) Li holding the key sponsor stake.
In 2025, the company formalized a two-step merger structure with Taiwanese biotech firm 'SL Bio Ltd.' Upon completion, HSPT and SL Bio will become subsidiaries of SL Science Holding, whose common stock is expected to trade on the Nasdaq Global Market under the 'SLBT' ticker. The SPAC is requesting a deadline extension to push the merger process forward.
💰 How does it make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Operating Revenue | None | A SPAC has no operations of its own and searches for a merger target |
| Trust Account Interest | Primary Funding Source | Funds raised through the IPO are held in a trust account |
By the nature of a SPAC, there is no meaningful revenue or earnings at this stage. Funds raised through the IPO are held in a trust account, generating only interest income until the merger closes. After the merger, the financial profile will shift to reflect SL Bio's business structure.
Market cap and company scaleThe market cap stands at $34.0M, roughly About 0% of Samsung Electronics' market cap. The number of employees is 2 people.
The market cap is close to the trust asset level and could fluctuate significantly depending on whether the merger closes and the valuation assigned to SL Bio.
📈 Outlook and stock price flow
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe outlook hinges on whether the SL Bio merger actually closes and on the post-merger business growth. With SL Bio reportedly proposing a large valuation, the key question is whether actual earnings and pipeline progress can support it. Until the merger closes, the stock remains largely an event-driven investment with trust protection.
By the nature of a SPAC, traditional metrics such as $0.14 and 3.7% have limited reference value, and SL Bio's post-merger financial reality will become the primary valuation yardstick.
⚔️ Key competitive strengths and risks
While the confirmed merger target and trust asset protection are advantages, SPAC-specific variables such as an overvalued target and redemption risk coexist.
💪 Key Competitive Strengths
⚠️ Key Risks
Comparisons include Asia biotech SPAC merger cases and Taiwan-listed biotech firms, while clinical-stage biotech more broadly can be benchmarked against Moderna (MRNA) and Regeneron (REGN) for sector trends.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | $136.62 | +0.7% | $54.5B | - | 8.1 | -39% | - |
| REGN | Regeneron Pharmaceuticals Inc | $793.77 | -1.7% | $81.7B | 19.6 | 2.6 | 14.04% | 0.5% |
| GILD | Gilead Sciences Inc | $144.81 | -0.6% | $179.6B | - | 15.2 | -20.57% | 2.24% |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Co | $63.75 | -1.0% | $130.2B | 14.0 | 5.8 | 46.7% | 3.67% |
| PFE | Pfizer Inc | $27.65 | -0.5% | $157.6B | 36.6 | 1.9 | 4.99% | 6.23% |
| VRTX | Vertex Pharmaceuticals Inc | $514.56 | -1.3% | $130.4B | 29.9 | 6.4 | 23.54% | - |
✅ Investor checkpoints
The appropriate way to approach HSPT is as 'a SPAC betting on the completion of the SL Bio merger.' Merger closing and valuation verification are the key checkpoints.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 📅 Merger Closing | Timing and progress of the SL Bio merger | Needs verification |
| 🏦 Trust Assets & Redemptions | Per-share trust value and shareholder redemption rate | Monitoring |
| 💎 SL Bio Valuation | Whether the proposed deal value is supported by actual earnings | Needs verification |
| ⏳ Deadline Extension | Approval of SPAC merger deadline extension | Needs verification |
Major risk factors include a failed merger, large-scale redemptions, Taiwan/China-related geopolitical risk, post-merger valuation repricing, and SPAC-specific volatility.
HSPT is a SPAC on the cusp of merging with Taiwanese biotech firm SL Bio. It is advisable to review the merger closing, valuation, and redemption risks together before taking a cautious approach.
Check Horizon Space Acquisition II's real-time quotes, technical indicators, and peer comparison at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free